PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Effect of cilostazol in experimental model of degloving injuries in rat limbs.

Abstract To evaluate the effect of the cilostazol on the evolution of partially avulsed flaps, using experimental model of cutaneous degloving in rat limbs.
PMID
Related Publications

Suppression of experimental abdominal aortic aneurysm in a rat model by the phosphodiesterase 3 inhibitor cilostazol.

Dipyrone increases the blood flow of arterial dorsal skin flaps.

The protective effect of cilostazol on transverse rectus abdominis myocutaneous flap in rats.

Oral administration of cilostazol improves survival rate after rat liver ischemia/reperfusion injury.

A comparison of rat degloving injury models.

Authors

Mayor MeshTerms

Disease Models, Animal

Keywords
Journal Title acta cirurgica brasileira
Publication Year Start




PMID- 29768532
OWN - NLM
STAT- MEDLINE
DCOM- 20180529
LR  - 20180529
IS  - 1678-2674 (Electronic)
IS  - 0102-8650 (Linking)
VI  - 33
IP  - 4
DP  - 2018 Apr
TI  - Effect of cilostazol in experimental model of degloving injuries in rat limbs.
PG  - 296-305
LID - S0102-86502018000400296 [pii]
LID - 10.1590/s0102-865020180040000001 [doi]
AB  - PURPOSE: To evaluate the effect of the cilostazol on the evolution of partially
      avulsed flaps, using experimental model of cutaneous degloving in rat limbs.
      METHODS: A controlled and randomized experimental study was carried out in which 
      the blood flow and the percentage of flap necrosis were evaluated. We compared
      the study group, which received cilostazol, and the control group, which received
      enteral saline solution in the postoperative period. The blood flow in the flap
      was evaluated through Laser Doppler flowmetry, and a planimetry using the IMAGE
      J(R) software was employed for the calculation of the area of necrosis. RESULTS: 
      Enteral administration of cilostazol was associated with a higher mean blood flow
      in all regions of the flap, with a statistically significant difference in the
      proximal and middle regions (p<0.001) and a lower percentage of necrotic area in 
      the flap (p<0.001). CONCLUSION: Postoperative enteral administration of
      cilostazol increased blood flow and decreased the total area of necrosis of
      avulsed cutaneous flaps of rat limbs.
FAU - Pazio, Andre
AU  - Pazio A
AD  - MD, Resident, Division of Plastic Surgery, Department of Surgery, Clinics
      Hospital, Universidade Ferederal do Parana (UFPR), Curitiba-PR, Brazil.
      Scientific and intellectual content of the study, analysis and interpretation of 
      data, technical procedures, statistical analysis, manuscript preparation and
      writing.
FAU - Santos, Vital Burko
AU  - Santos VB
AD  - Graduate student, Pontificia Universidade Catolica do Parana (PUC-PR),
      Curitiba-PR, Brazil. Acquisition, analysis and interpretation of data; technical 
      procedures; manuscript preparation.
FAU - Salles Junior, Guatacara Schenfelder
AU  - Salles Junior GS
AD  - PhD, Associate Professor, Experimental Surgery Division, School of Medicine,
      PUC-PR, Curitiba-PR, Brazil. Scientific, intellectual, conception and design of
      the study; critical revision; final approval.
LA  - eng
PT  - Journal Article
PL  - Brazil
TA  - Acta Cir Bras
JT  - Acta cirurgica brasileira
JID - 9103983
RN  - 0 (Phosphodiesterase 3 Inhibitors)
RN  - 0 (Tetrazoles)
RN  - N7Z035406B (cilostazol)
SB  - IM
MH  - Animals
MH  - Degloving Injuries/*drug therapy/pathology/surgery
MH  - *Disease Models, Animal
MH  - Humans
MH  - Laser-Doppler Flowmetry
MH  - Lower Extremity/blood supply/injuries/pathology
MH  - Male
MH  - Necrosis/drug therapy
MH  - Phosphodiesterase 3 Inhibitors/pharmacology/*therapeutic use
MH  - Random Allocation
MH  - Rats, Wistar
MH  - Reference Values
MH  - Regional Blood Flow/drug effects
MH  - Reproducibility of Results
MH  - Surgical Flaps
MH  - Tetrazoles/pharmacology/*therapeutic use
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2018/05/17 06:00
MHDA- 2018/05/31 06:00
CRDT- 2018/05/17 06:00
PHST- 2017/12/16 00:00 [received]
PHST- 2018/03/20 00:00 [accepted]
PHST- 2018/05/17 06:00 [entrez]
PHST- 2018/05/17 06:00 [pubmed]
PHST- 2018/05/31 06:00 [medline]
AID - S0102-86502018000400296 [pii]
AID - 10.1590/s0102-865020180040000001 [doi]
PST - ppublish
SO  - Acta Cir Bras. 2018 Apr;33(4):296-305. doi: 10.1590/s0102-865020180040000001.